Elias Dominique, Ouellet Jean-Francois, De Baère Thierry, Lasser Philippe, Roche Alain
Department of Surgical Oncology and the Interventional Radiology Unit, Institut Gustave Roussy, Villejuif, Cedex, France.
Surgery. 2002 Mar;131(3):294-9. doi: 10.1067/msy.2002.120234.
Some patients cannot undergo curative surgical procedures for liver metastases because of the risk of severe postoperative hepatic failure, which stems from a too-small future remaining liver (FRL). Preoperative portal vein embolization (PVE) is an effective means of creating hypertrophy of the FRL, thus permitting safe hepatic resection. The aim of this retrospective study was to investigate the long-term results of this technique.
Sixty-eight patients underwent PVE. Of those, 60 (88%) subsequently underwent hepatic resection. Indication for PVE was an estimated FRL ratio (assessed by volumetric computed tomography) of less than 30%. However, if the patient had undergone multiple courses of chemotherapy, the threshold was 40%. The origin of the primary neoplasm was colorectal in 41 patients (68%); in the remaining 19 (32%), the primary neoplasms originated at other sites.
Mean growth of the estimated FRL measured by computed tomography 1 month after PVE was 13%. Major complications after hepatectomy occurred in 27% of the patients, and the operative mortality rate was 3%. For the 60 patients who underwent PVE followed by hepatic resection, the 5-year overall survival rate and the disease-free survival rate were 34% and 24%, respectively. The 5-year overall survival rate and the disease-free survival rate of patients with colorectal metastases only were 37% and 21%, respectively.
The long-term survival rate after PVE followed by resection is comparable with the survival rate obtained after resection without preoperative PVE. The 5-year survival rate of patients undergoing PVE followed by hepatectomy justifies the use of this technique. This technique thus increases the suitability of resection as a treatment choice for patients with liver metastases. PVE should number among the therapeutic options available to every hepatic surgeon.
部分患者因术后发生严重肝衰竭风险而无法接受肝转移瘤的根治性手术,这一风险源于未来剩余肝脏(FRL)过小。术前门静脉栓塞术(PVE)是促使FRL肥大的有效方法,从而使肝切除手术得以安全进行。本回顾性研究旨在探讨该技术的长期效果。
68例患者接受了PVE。其中,60例(88%)随后接受了肝切除手术。PVE的指征为预计FRL比例(通过容积计算机断层扫描评估)小于30%。然而,如果患者接受过多个疗程的化疗,该阈值则为40%。41例患者(68%)的原发肿瘤起源于结肠直肠;其余19例(32%)的原发肿瘤起源于其他部位。
PVE术后1个月通过计算机断层扫描测得的预计FRL平均增长为13%。肝切除术后主要并发症发生率为27%,手术死亡率为3%。对于60例接受PVE后再行肝切除的患者,5年总生存率和无病生存率分别为34%和24%。仅发生结肠直肠转移的患者5年总生存率和无病生存率分别为37%和21%。
PVE后再行肝切除的长期生存率与术前未行PVE直接肝切除的生存率相当。接受PVE后再行肝切除患者的5年生存率证明了该技术的应用价值。因此,该技术提高了肝转移瘤患者选择肝切除治疗的适宜性。PVE应成为每位肝脏外科医生可采用的治疗选择之一。